Side-by-side · Research reference
BPC-157vsGLP-1 (7-37)
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2HUMAN-REVIEWED9/53 cited
BHuman-MechanisticHUMAN-REVIEWED16/43 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
SQ or IM · Local · Once or twice daily
GLP-1 (7-37)
Incretin Hormone · Native Peptide
Research use only · IV/SC in experimental settings
01Mechanism of Action
Parameter
BPC-157
GLP-1 (7-37)
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2011Sikiric 2018
GLP-1 receptor (class B GPCR)Koole 2015
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2011
GLP-1R activation → cAMP production → PKA signaling → insulin secretion (pancreatic β-cells)Lu 2025Koole 2015
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Feedback intact?
No known endogenous receptor; mechanism still under investigation
Yes — physiological secretion and degradation preserved
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
Endogenous peptide cleaved from proglucagon in intestinal L cells; secreted postprandially
Antibody development
—
—
02Dosage Protocols
Parameter
BPC-157
GLP-1 (7-37)
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
—
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
—
Lower / starter dose
200 mcg / day
Conservative starter for new users.
—
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
—
Reconstitution
Bacteriostatic water, 1–2 mL
—
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
—
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
~2 minutes (plasma)Alavi 2021Ding 2017
Requires continuous infusion for sustained effect.
Clinical use
—
None — native GLP-1 not used therapeutically
Engineered analogues (semaglutide, liraglutide) used clinically.Friedman 2024
Research dosing
—
Variable — 0.1–10 nmol/kg in animal models
Used as reference standard for analogue comparison.
Modified analogues
—
t½ extended to 13 h (liraglutide), 165 h (semaglutide)
Via DPP-4 resistance + fatty acid acylation.
03Metabolic / Fat Loss Evidence
Parameter
BPC-157
GLP-1 (7-37)
Mechanism
—
Native GLP-1 efficacy
—
Minimal — rapid degradation prevents sustained appetite suppression
Gastric emptying
—
Delayed in animal models, contributing to satiety
Body weight impact
—
Not observed with native GLP-1 — requires analogue formulations
04Side Effects & Safety
Parameter
BPC-157
GLP-1 (7-37)
Injection site reaction
Mild irritation (anecdotal)
—
GI symptoms
None reported in PL-14736 Phase 2
—
Cardiovascular
Not reported
—
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
—
Long-term safety
Unknown beyond Phase 2 trial duration
—
Drug interactions
None established
—
Native GLP-1
—
Well-tolerated in research settings; no prolonged exposure data
Hypoglycemia risk
—
Low — insulin secretion is glucose-dependent
Analogue side effects
—
Nausea, vomiting, diarrhea (GLP-1R agonists)
Not applicable to native GLP-1 due to non-therapeutic use.
GLP-1 resistance
—
High glucose-induced PKCβ overexpression may reduce GLP-1 responsiveness in endothelial cellsPujadas 2016
Absolute Contraindications
BPC-157
- ·Pregnancy / breastfeeding
- ·Known active malignancy (theoretical VEGF concern)
GLP-1 (7-37)
—Relative Contraindications
BPC-157
- ·History of cancer
- ·Concurrent VEGF inhibitor therapy (theoretical)
- ·Acute thrombotic events
GLP-1 (7-37)
—05Administration Protocol
Parameter
BPC-157
GLP-1 (7-37)
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Native GLP-1(7-37) is not formulated for therapeutic use. Administered IV or SC in experimental protocols to study GLP-1R pharmacology and as reference standard for analogue development.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
Lyophilised peptide stored at -20°C or below. Reconstituted solutions should be prepared fresh and used immediately due to rapid degradation.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
For therapeutic GLP-1R activation, use FDA-approved long-acting analogues: semaglutide (once weekly), liraglutide (once daily), dulaglutide (once weekly), or exenatide (twice daily or once weekly).
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
—
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
—
06Stack Synergy
BPC-157
+ TB-500
StrongBPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.
- BPC-157
- 250–500 mcg SQ · daily
- TB-500
- 2 mg SQ · 2× per week
- Primary benefit
- Tendon/ligament/muscle repair via complementary angiogenesis + migration
GLP-1 (7-37)
— no documented stacks